Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -393K | -746K | -770K | -604K | -26K |
| Operating Income | -4M | -5M | -6M | -8M | -1M |
| EBITDA | -3M | -4M | -5M | -7M | -1M |
| Net Income | -4M | -4M | -6M | -7M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$12.01
-18.96% today
Window Change
-49.75%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regencell Bioscience Holdings Limited (RGC) is a Healthcare stock with a market cap of $14.40B and listed on NASDAQ. The stock last traded around $12.01 and down 49.7% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +17.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +17.2%, free cash flow +18.5% with operating margin 0.0% and ROIC -69.8%. Stock Foundry combines RGC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RGC Max Drawdown
-50.31%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RGC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.3M
+81.9% YoY
Free Cash Flow
-$767.3K
+87.3% YoY
Revenue Growth
+0.0%
EPS Growth
+17.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -393K | -746K | -770K | -604K | -26K |
| Operating Income | -4M | -5M | -6M | -8M | -1M |
| EBITDA | -3M | -4M | -5M | -7M | -1M |
| Net Income | -4M | -4M | -6M | -7M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 3M | 2M | 6M | 59K |
| Total Assets | 6M | 8M | 13M | 18M | 340K |
| Total Liabilities | 895K | 220K | 632K | 938K | 4M |
| Shareholder Equity | 5M | 8M | 12M | 17M | -4M |
| Total Debt | 544K | 86K | 464K | 771K | 4M |
| Net Debt | -2M | -3M | -1M | -6M | 4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
767K
+85.4% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
767K
+87.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.9%
Debt / Equity
0.11x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.